The Claim
Adults with obesity or overweight who stop taking tirzepatide regain a substantial proportion of lost weight, with 83.4% of participants switching to placebo failing to maintain at least 80% of initial weight loss at 52 weeks, compared to only 10.5% of those who continued tirzepatide (P < .001).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Obesity or overweight adults who stop taking tirzepatide regain most of the lost weight. Only 10.5% of those who continue the drug maintain at least 80% of their weight loss after one year, while 83.4% of those who stop fail to maintain that level.
See the scientific wording
After stopping tirzepatide, adults with obesity or overweight regain a substantial proportion of lost weight: 83.4% of participants who switched to placebo failed to maintain at least 80% of their initial weight loss at 52 weeks, compared to only 10.5% of those who continued tirzepatide (P < .001).
Tirzepatide works by activating GIP and GLP-1 receptors in the brain and body, which reduces appetite and improves metabolism, leading to weight loss. When a person stops taking tirzepatide, the receptors are no longer activated. This loss of receptor activation causes appetite to return to normal or even increase, and metabolism slows down. As a result, the body regains the lost weight.
What the research says
1 studyThe study found that about 84 out of 100 people who stopped taking tirzepatide regained most of the weight they lost, but only about 11 out of 100 who kept taking it had that problem.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.